Breaking News

Hepion Prescribed drugs Declares Initiation of Section 2b

– Hepion Screens First Topic in Biopsy-Confirmed F2/F3 NASH Research – – Topics can be Evaluated on Three Doses of Rencofilstat for a One-year Interval – EDISON, N.J., Aug. 31, 2022 (GLOBE NEWSWIRE) — Hepion Prescribed drugs, Inc. (NASDAQ:HEPA), a scientific stage biopharmaceutical firm targeted on Synthetic Intelligence (“AI”)-driven therapeutic drug improvement for the remedy […]